These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 8874343)

  • 1. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
    Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
    J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
    Bührer C; Hartmann R; Fengler R; Schober S; Arlt I; Loewke M; Henze G
    Blood; 1994 Jun; 83(12):3468-72. PubMed ID: 8204875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
    Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
    Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
    Schrappe M; Aricò M; Harbott J; Biondi A; Zimmermann M; Conter V; Reiter A; Valsecchi MG; Gadner H; Basso G; Bartram CR; Lampert F; Riehm H; Masera G
    Blood; 1998 Oct; 92(8):2730-41. PubMed ID: 9763557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
    Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
    J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
    Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
    J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
    Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
    Reiter A; Schrappe M; Ludwig WD; Hiddemann W; Sauter S; Henze G; Zimmermann M; Lampert F; Havers W; Niethammer D
    Blood; 1994 Nov; 84(9):3122-33. PubMed ID: 7949185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
    Veerman AJ; Hählen K; Kamps WA; Van Leeuwen EF; De Vaan GA; Solbu G; Suciu S; Van Wering ER; Van der Does-Van der Berg A
    J Clin Oncol; 1996 Mar; 14(3):911-8. PubMed ID: 8622039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone.
    Felice MS; Zubizarreta PA; Alfaro EM; Sackmann-Muriel F
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):411-5. PubMed ID: 11878573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.
    von Stackelberg A; Hartmann R; Bührer C; Fengler R; Janka-Schaub G; Reiter A; Mann G; Schmiegelow K; Ratei R; Klingebiel T; Ritter J; Henze G;
    Blood; 2008 Mar; 111(5):2573-80. PubMed ID: 18089849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association.
    Uderzo C; Valsecchi MG; Bacigalupo A; Meloni G; Messina C; Polchi P; Di Girolamo G; Dini G; Miniero R; Locatelli F
    J Clin Oncol; 1995 Feb; 13(2):352-8. PubMed ID: 7844596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.
    Henze G; Fengler R; Hartmann R; Kornhuber B; Janka-Schaub G; Niethammer D; Riehm H
    Blood; 1991 Sep; 78(5):1166-72. PubMed ID: 1878583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.